Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
246 studies found for:    "Adenocarcinoma of lung"
Show Display Options
Rank Status Study
21 Recruiting Low-Dose Acetylsalicylic Acid in Treating Patients With Stage I-III Non-Small Cell Lung Cancer
Conditions: Adenocarcinoma of the Lung;   Recurrent Non-small Cell Lung Cancer;   Stage IA Non-small Cell Lung Cancer;   Stage IB Non-small Cell Lung Cancer;   Stage IIA Non-small Cell Lung Cancer;   Stage IIB Non-small Cell Lung Cancer;   Stage IIIA Non-small Cell Lung Cancer;   Stage IIIB Non-small Cell Lung Cancer
Interventions: Drug: acetylsalicylic acid;   Other: laboratory biomarker analysis
22 Recruiting Registry Measuring the Impact of Adding RNA Expression Testing on Referral Decisions in Early Stage Lung Cancer Patients (ONC003_CT Surgeon Specific)
Conditions: Lung Cancer;   NSCLC;   Lung Adenocarcinoma
Intervention:
23 Active, not recruiting
Has Results
Erlotinib Hydrochloride With or Without Carboplatin and Paclitaxel in Treating Patients With Stage III-IV Non-Small Cell Lung Cancer
Conditions: Adenocarcinoma of the Lung;   Adenosquamous Cell Lung Cancer;   Bronchoalveolar Cell Lung Cancer;   Recurrent Non-small Cell Lung Cancer;   Stage IIIB Non-small Cell Lung Cancer;   Stage IV Non-small Cell Lung Cancer
Interventions: Drug: erlotinib hydrochloride;   Drug: paclitaxel;   Drug: carboplatin
24 Recruiting A Phase 3 Study of Ganetespib in Combination With Docetaxel Versus Docetaxel Alone in Patients With Advanced NSCLC
Conditions: Non-Small-Cell Lung Adenocarcinoma;   Non-small Cell Lung Cancer Stage IIIB;   Non-small Cell Lung Cancer Stage IV;   Non-small Cell Lung Cancer Metastatic
Interventions: Drug: Arm A: single agent docetaxel;   Drug: Arm B: Combination of ganetespib and docetaxel
25 Completed Sorafenib in BAC or Never-Smokers With Lung Adenocarcinoma
Condition: Lung Cancer
Intervention: Drug: sorafenib
26 Recruiting Comparison of Two Therapeutic Strategies in Patients With Non-squamous Non-small Cell Lung Cancer (NSCLC) With Asymptomatic Brain Metastases
Conditions: Non-small Cell Lung Cancer Metastatic;   Non Epidermoid;   Non-small Cell Lung Cancer;   Adenocarcinoma of Lung Metastatic to Brain;   Cerebral Metastases;   Cerebral Radiotherapy;   Brain Radiotherapy;   Bevacizumab
Interventions: Drug: Cisplatin;   Drug: Pemetrexed;   Drug: Bevacizumab;   Radiation: Cerebral Radiotherapy
27 Not yet recruiting A Phase II, Open Label, Multiple Arm Study of AUY922, BYL719, INC280, LDK378 and MEK162 in Chinese Patients With Advanced Non-small Cell Lung Cancer
Condition: Adenocarcinoma Lung Cancer
Interventions: Drug: AUY922;   Drug: BYL719;   Drug: INC280;   Drug: LDK378;   Drug: MEK162
28 Completed Neoadjuvant Pemetrexed, Cisplatin and Bevacizumab in Unresectable, Locally Advanced Lung Adenocarcinoma
Condition: Lung Cancer
Intervention: Drug: Neoadjuvant Bevacizumab
29 Active, not recruiting Safety and Pharmacology Study of SNX-5422 in Subjects With Resistant Lung Adenocarcinoma
Condition: Cancer
Intervention: Drug: SNX-5422
30 Recruiting Intercalated Administration of PamCis With Gefitinib or Placebo as First Line Lung Adenocarcinoma in Never Smokers
Conditions: Non Small Cell Lung Cancer;   Adenocarcinoma
Interventions: Drug: Gefitinib;   Drug: Placebo;   Drug: Pemetrexed plusCIsplatin
31 Recruiting A Phase II Study to Assess Efficacy of Combined Treatment With Erlotinib (Tarceva) and Silybin-phytosome (Siliphos) in Patients With EGFR Mutant Lung Adenocarcinoma
Condition: Carcinoma, Non-Small-Cell Lung
Interventions: Drug: Erlotinib;   Dietary Supplement: Silybin-phytosome
32 Recruiting Whole-Exome Sequencing (WES) of Cancer Patients
Conditions: Lung Adenocarcinoma;   Colon Adenocarcinoma
Intervention:
33 Recruiting Veliparib With or Without Radiation Therapy, Carboplatin, and Paclitaxel in Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery
Conditions: Adenosquamous Lung Carcinoma;   Bronchioloalveolar Carcinoma;   Large Cell Lung Carcinoma;   Lung Adenocarcinoma;   Squamous Cell Lung Carcinoma;   Stage IIIA Non-Small Cell Lung Cancer;   Stage IIIB Non-Small Cell Lung Cancer
Interventions: Drug: Veliparib;   Other: Hydrocortisone/Placebo;   Drug: Carboplatin;   Drug: Paclitaxel;   Radiation: 3-Dimensional Conformal Radiation Therapy
34 Active, not recruiting MK2206 and Erlotinib Hydrochloride in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Progressed After Previous Response to Erlotinib Hydrochloride Therapy
Conditions: Adenosquamous Lung Carcinoma;   Bronchioloalveolar Carcinoma;   Large Cell Lung Carcinoma;   Lung Adenocarcinoma;   Recurrent Non-Small Cell Lung Carcinoma;   Squamous Cell Lung Carcinoma
Interventions: Drug: Akt Inhibitor MK2206;   Drug: Erlotinib Hydrochloride;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study
35 Recruiting Erlotinib Hydrochloride or Crizotinib and Chemoradiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer
Conditions: Bronchioloalveolar Carcinoma;   Large Cell Lung Carcinoma;   Lung Adenocarcinoma;   Stage IIIA Non-Small Cell Lung Cancer;   Stage IIIB Non-Small Cell Lung Cancer
Interventions: Drug: Erlotinib Hydrochloride;   Drug: Crizotinib;   Radiation: Intensity-Modulated Radiation Therapy;   Radiation: 3-Dimensional Conformal Radiation Therapy;   Drug: Cisplatin;   Drug: Etoposide;   Drug: Paclitaxel;   Drug: Carboplatin;   Other: Laboratory Biomarker Analysis
36 Not yet recruiting Blood Detection of EGFR Mutation For Iressa Treatment
Condition: Lung Adenocarcinoma
Intervention: Drug: Gefitinib
37 Active, not recruiting Paclitaxel, Carboplatin, and Bevacizumab With or Without Cixutumumab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer
Conditions: Bronchioloalveolar Carcinoma;   Large Cell Lung Carcinoma;   Lung Adenocarcinoma;   Recurrent Non-Small Cell Lung Carcinoma;   Stage IV Non-Small Cell Lung Cancer
Interventions: Biological: Cixutumumab;   Drug: Paclitaxel;   Drug: Carboplatin;   Biological: Bevacizumab
38 Recruiting Study of Positron Emission Tomography and Computed Tomography in Guiding Radiation Therapy in Patients With Stage III Non-Small Cell Lung Cancer
Conditions: Adenosquamous Lung Carcinoma;   Bronchioloalveolar Carcinoma;   Large Cell Lung Carcinoma;   Lung Adenocarcinoma;   Squamous Cell Lung Carcinoma;   Stage IIIA Non-Small Cell Lung Cancer;   Stage IIIB Non-Small Cell Lung Cancer
Interventions: Radiation: External Beam Radiation Therapy;   Radiation: Image-Guided Adaptive Radiation Therapy;   Drug: Paclitaxel;   Drug: Carboplatin;   Radiation: Fludeoxyglucose F-18;   Procedure: Positron Emission Tomography;   Procedure: Computed Tomography;   Other: Laboratory Biomarker Analysis
39 Completed Photodynamic Therapy in Treating Patients With Lung Cancer
Conditions: Adenocarcinoma of the Lung;   Large Cell Lung Cancer;   Recurrent Non-small Cell Lung Cancer;   Squamous Cell Lung Cancer;   Stage 0 Non-small Cell Lung Cancer
Interventions: Drug: HPPH;   Drug: photodynamic therapy;   Procedure: therapeutic bronchoscopy
40 Completed Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Advanced, Metastatic, or Recurrent Non-Small Cell Lung Cancer
Conditions: Adenocarcinoma of the Lung;   Bronchoalveolar Cell Lung Cancer;   Large Cell Lung Cancer;   Recurrent Non-small Cell Lung Cancer;   Stage IIIB Non-small Cell Lung Cancer;   Stage IV Non-small Cell Lung Cancer
Interventions: Drug: paclitaxel;   Drug: carboplatin;   Biological: bevacizumab;   Other: laboratory biomarker analysis

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years